Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

TheUnmaker May. 8 at 4:19 PM

$TNXP I have a big gap in my teeth @ $59 that needs to be filled. Please and thank you in advance. $PFE $LLY $PG $JNJ

0 · Reply

FreeMoneyandFed May. 8 at 4:12 PM

$SPY $QQQ $JNJ $MRNA Should have got into MRNA yesterday. saw it coming but didn't act !

0 · Reply

TheUnmaker May. 8 at 3:43 PM

$TNXP nice dip today.. glad to have bought more. $100+ stock after recent news. 35M+ new patients added to coverage is huge. $PFE $JNJ $LLY $PG

1 · Reply

Suite510 May. 8 at 11:03 AM

$JNJ $KVUE $SPX $ABT baby issues 😂 'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

0 · Reply

peloswing May. 8 at 5:09 AM

$JNJ Johnson & Johnson just broke down out of uptrend it has sustained since Summer 2025. Looking like the next support exists in the $210-213 area (shaded region), giving about ~$10 of room down in the short-term 🔻

0 · Reply

FreeMoneyandFed May. 7 at 9:09 PM

$SPY $QQQ $JNJ $MRNA now they are starting the panic on hantavirus "contracted the virus on a pre-cruise birdwatching tour at a local landfill. " who the hell goes to a birdwatching tour to a landfill ? WTF?

3 · Reply

TCLutz May. 7 at 8:32 PM

$OSRH I got what I needed! Didn’t know they signed an NDA for their glucose monitor with china’s largest pharma distributor! 🤯💥 Don’t let the AH fxckery shake you out of your shares. This is typical conference manipulation. Gonna let it all ride! 💪🫡🔥 $SPY $JNJ $MRNA $PF.X

0 · Reply

DragonAlgoTrades May. 7 at 4:34 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-05-15 | Strike: $225.00 | Type: CALL Option Plan (premium): Entry: $3.02 Stop: $2.17 TP1: $3.93 TP2: $5.13 TP3: $7.25 🔗 https://dragonalgo.com

0 · Reply

Suite510 May. 7 at 1:49 AM

$JNJ $KVUE $SPX 🤣😝

0 · Reply

Suite510 May. 7 at 1:48 AM

$JNJ $KVUE $SPX Rut Ro legal boat to sink again 🤣 Ex-FDA Chief Testifies 100s Of JNJ Docs Tie Asbestos To Talc A former U.S. Food and Drug Administration commissioner on Tuesday testified in a Los Angeles bellwether trial over claims JNJ talc products caused deadly ovarian cancer in three women, saying hundreds of internal company documents reveal the company knew for decades that its talc contained asbestos.

0 · Reply

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 3 days ago

CVS to drop J&J's Stelara from its main formularies

CVS

2026-05-05T12:35:53.000Z - 3 days ago

Johnson & Johnson announces results from Phase 3 FUZION study of tremfya

2026-05-05T12:12:17.000Z - 3 days ago

Johnson & Johnson announces Phase 2b data from JNJ-4804 studies

May 5, 2026, 8:05 AM EDT - 3 days ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 3 days ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

2026-05-05T11:35:18.000Z - 3 days ago

Johnson & Johnson announces study of OTTAVA System met primary endpoints

May 5, 2026, 7:00 AM EDT - 3 days ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

2026-05-04T21:40:39.000Z - 3 days ago

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

NBTX

2026-05-04T12:39:14.000Z - 4 days ago

Johnson & Johnson’s Caplyta shows greater efficacy in major depressive disorder

May 4, 2026, 8:00 AM EDT - 4 days ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 6 days ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

2026-04-30T16:01:52.000Z - 8 days ago

Johnson & Johnson appoints Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 8 days ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 10 days ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 10 days ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 11 days ago

J&J sees AI halving the time to generate drug development leads

2026-04-27T12:10:52.000Z - 11 days ago

Johnson & Johnson’s Imaavy granted Priority Review by FDA in hemolytic anemia

Apr 27, 2026, 8:03 AM EDT - 11 days ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 13 days ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 14 days ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 15 days ago

Johnson & Johnson Transcript: AGM 2026

2026-04-22T12:45:27.000Z - 16 days ago

Johnson & Johnson reports new data from Phase 3 Vivacity-MG3 study

Apr 22, 2026, 8:05 AM EDT - 16 days ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 16 days ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 16 days ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 17 days ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 20 days ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 20 days ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 15, 2026, 4:11 PM EDT - 22 days ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 14, 2026, 10:51 AM EDT - 24 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 24 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 8:30 AM EDT - 24 days ago

Johnson & Johnson Earnings Call Transcript: Q1 2026

Apr 14, 2026, 6:55 AM EDT - 24 days ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 24 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 24 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 24 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 24 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 12, 2026, 2:00 PM EDT - 26 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 8, 2026, 10:41 AM EDT - 4 weeks ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 5 weeks ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 5 weeks ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 5 weeks ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 6 weeks ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 7 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 7 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 7 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 7 weeks ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 7 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 7 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 10, 2026, 11:30 AM EDT - 2 months ago

Johnson & Johnson Transcript: Barclays 28th Annual Global Healthcare Conference

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 2 months ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 2 months ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 2 months ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 11:10 AM EST - 2 months ago

Johnson & Johnson Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:03 AM EST - 2 months ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

TheUnmaker May. 8 at 4:19 PM

$TNXP I have a big gap in my teeth @ $59 that needs to be filled. Please and thank you in advance. $PFE $LLY $PG $JNJ

0 · Reply

FreeMoneyandFed May. 8 at 4:12 PM

$SPY $QQQ $JNJ $MRNA Should have got into MRNA yesterday. saw it coming but didn't act !

0 · Reply

TheUnmaker May. 8 at 3:43 PM

$TNXP nice dip today.. glad to have bought more. $100+ stock after recent news. 35M+ new patients added to coverage is huge. $PFE $JNJ $LLY $PG

1 · Reply

Suite510 May. 8 at 11:03 AM

0 · Reply

peloswing May. 8 at 5:09 AM

0 · Reply

FreeMoneyandFed May. 7 at 9:09 PM

3 · Reply

TCLutz May. 7 at 8:32 PM

0 · Reply

DragonAlgoTrades May. 7 at 4:34 AM

0 · Reply

Suite510 May. 7 at 1:49 AM

$JNJ $KVUE $SPX 🤣😝

0 · Reply

Suite510 May. 7 at 1:48 AM

0 · Reply

bbq1232 May. 6 at 3:42 PM

$JNJ wild at this point. No love

0 · Reply

biotech May. 6 at 1:59 PM

$SGMO MAY 12 3:30-5pm 𝙜𝙚𝙣𝙚 𝙚𝙙𝙞𝙩𝙞𝙣𝙜 𝙨𝙚𝙨𝙨𝙞𝙤𝙣 on 𝙉𝙚𝙭𝙩-𝙜𝙚𝙣𝙚𝙧𝙖𝙩𝙞𝙤𝙣 𝙥𝙡𝙖𝙩𝙛𝙤𝙧𝙢𝙨 𝙛𝙤𝙧 𝙥𝙧𝙚𝙘𝙞𝙨𝙚 𝙩𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘 𝙜𝙚𝙣𝙤𝙢𝙚 𝙚𝙙𝙞𝙩𝙞𝙣𝙜 𝙖𝙣𝙙 𝙞𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙞𝙤𝙣 #MINT for next genereation CAR-T $GILD $NVS $JNJ $BMY

0 · Reply

clan May. 6 at 12:46 PM

$MNKD $JNJ @DRFSR @pierrules For the good of all Mannkind, MNKD-1501 announced as Technoralinepagosphere DPI deserves a ...

0 · Reply

TheUnmaker May. 6 at 11:30 AM

$TNXP We are just getting started.. Easily going to $30+ very fast! $LLY $JNJ $PG $PFE

0 · Reply

Quantumup May. 6 at 11:12 AM

Stifel y'day⬆️ $SYRE's PT to $107 (was $92), reit'd at Buy/said: Following best-in-class UC PoC data for SPY001 (α4β7), SYRE is well-positioned heading into additional PoC cohorts for SPY002 (TL1A) and SPY003 (IL-23p19) in mid-year/3Q26. $JNJ TAK APGE ABVX $ABBV Here's what else Stifel had to say: https://x.com/Quantumup1/status/2051982840607215753?s=20

0 · Reply

TheUnmaker May. 6 at 11:03 AM

$TNXP We will run now.. she's ready! $PFE $NVAX $LLY $JNJ

0 · Reply

DragonAlgoTrades May. 6 at 10:19 AM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-05-15 | Strike: $225.00 | Type: PUT Option Plan (premium): Entry: $2.77 Stop: $1.99 TP1: $3.60 TP2: $4.71 TP3: $6.65 🔗 https://dragonalgo.com

0 · Reply

TheUnmaker May. 5 at 6:57 PM

$TNXP Bring in the apes! $PFE $NBIS $LLY $JNJ

1 · Reply

RiskyAlpha May. 5 at 3:05 PM

$QQQ $JNJ Starting the day with a wide 4-leg parlay.

0 · Reply

STOCKPICKERTRADER May. 5 at 3:03 PM

$BSX just buy the dips and sell the stall areas to build out positions in the device makers as the $IHI begins to find its footing for some upside action $MDT $DHR $JNJ and plenty of others

0 · Reply

Framingtheworld May. 5 at 2:10 PM

$ATAI q2 is the expected timeline of a $2 billion partnership with possibly companies like $JNJ

2 · Reply

DragonAlgoTrades May. 5 at 1:26 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-05-08 | Strike: $225.00 | Type: CALL Option Plan (premium): Entry: $2.16 Stop: $1.56 TP1: $2.81 TP2: $3.67 TP3: $5.18 🔗 https://dragonalgo.com

0 · Reply

Market Cap	540.71B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.02
Forward PE	19.49
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	2,230,420
Avg Vol	7,802,602
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	18%
Beta	0.27
Analysts	Strong Sell
Price Target	$259.92